

THE ROLE OF XRPD IN ACCELERATING PHARMACEUTICAL PHASE IDENTIFICATION AND SELECTION

A. E. McKeown, A. Bak, C. K. Maguire, M. J. McNevin, N. N. Tsou,
T. Rhodes, A. S. Chin

Merck & Co., Inc, PO Box 2000, Rahway, NJ 07065, USA

As the pharmaceutical industry faces an ever more challenging and competitive environment, rapid and early phase selection is becoming of paramount importance. High throughput tools and techniques are therefore playing an increasing role in this arena to help quickly identify new and useful phases of a drug substance, and reduce the risk of failure in drug development.

The work described herein details fast and economical methods for the identification and evaluation of crystalline phases of drug substances, including neutral API, salts, co-crystals, and hydrates, solvates and polymorphs thereof. The merit of high throughput XRPD as one of the main analytical techniques used for rapid analysis of new pharmaceutical solid phases will be discussed, alongside tools for managing the large volume of data that are generated.